The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

HIV effort. More people than ever are receiving antiretroviral treatment and have viral suppression. Deaths from AIDS are at their lowest level for two decades. Yet despite this encouraging progress, ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

Women – especially teen girls and young women living in sub-Saharan Africa – are disproportionately impacted by <a ...

Gilead Sciences demonstrated positive momentum on the NASDAQ, with shares climbing 0.6 percent to $91.88. This upward trajectory is primarily attributed to groundbreaking results from clinical trials ...